Press Release

Burns & Levinson today announced that it represented Harvard Bioscience, Inc. (Nasdaq:HBIO) in its approximately $70 million acquisition of Data Sciences International, Inc. (DSI). The deal, which was announced on January 22, 2018, closed on January 31, 2018. Simultaneously, Burns represented Harvard Bioscience in its sale of its wholly-owned subsidiary Denville Scientific, Inc. to Thomas Scientific, LLC for approximately $20 million (including a $3 million earn-out provision).

In conjunction with the acquisition and sale, Burns also served as Harvard Bioscience’s counsel for a $64 million credit facility with Cerberus Business Finance, LLC, as administrative agent and collateral agent for the lenders.

Burns has represented Harvard Bioscience in three other acquisitions since 2014 – HEKA Electronik in 2015, and Triangle BioSystems, Inc. and Multi Channel Systems in 2014 – and the sale of Ahn Biotechnologie GmbH in 2016.

“Our entire organization has worked tirelessly over the last three years to build a foundation to be able to acquire and integrate a company like DSI. Burns & Levinson has been with us every step of the way, and their business savvy and technical expertise has played a significant role in helping Harvard Bioscience take this significant step forward in our strategic vision of the company,” said Jeffrey A. Duchemin, President and Chief Executive Officer of Harvard Bioscience.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.